A groundbreaking vaccine has been able to reverse cancer in nine patients, part of a trial, who received tailor-made jabs ...
On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned ...